Entera Bio Ltd. (ENTX)
Nasdaq · Healthcare · Biotechnology
$2.62−8.39%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $455M
- 52-week range
- $0.91 – $4.20
- 52-week change
- +55.43%
- EPS (trailing)
- −$0.36
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 13, 2026
Fiscal year to Dec 2025
- Revenue
- $42K (−76.80%)
- Net income
- −$11.4M
- Operating margin
- −27450.0%
- Diluted EPS
- $0.25
- Free cash flow
- −$7.5M
From the company’s annual report on SEC EDGAR.
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Headquarters: Jerusalem, Israel · 20 employees · enterabio.com